Daratumumab with lenalidomide and dexamethasone in relapsed or
refractory multiple myeloma patients – real world evidence
analysis

J 2023

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis

ŠTORK, Martin; Ivan SPICKA; Jakub RADOCHA; Jiri MINARIK; Tomas JELINEK et al.

Základní údaje

Originální název

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis

Autoři

Vydání

Annals of Hematology, NEW YORK, SPRINGER, 2023, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.000

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00130652

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; Treatment; Response rate; Relapse

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2024 08:08, Mgr. Tereza Miškechová

Anotace

V originále

We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of clinical trials in all major Czech hematology centers. As a reference, 531 RRMM patients treated with Rd were evaluated. Patients’ data were recorded in the Czech Registry of Monoclonal Gammopathies (RMG). Partial response (PR) or better response (ORR) was achieved in significantly more patients in Dara-Rd than in Rd group (91.2% vs. 69.9%; p < 0.001). The median progression free survival (PFS) was 26.9 months in the Dara-Rd and 12.8 months in the Rd group (p < 0.001). Median overall survival (OS) was not reached in the Dara-Rd compared to 27.2 months in the Rd group (p = 0.023). In patients with 1–3 previous treatment lines, there was significant PFS benefit of Dara-Rd compared to Rd (median PFS not reached vs. 13.2 months; p < 0.001). In patients with > 3 previous treatment lines, there was no significant PFS benefit of Dara-Rd treatment (7.8 months vs. 9.9 months; p = 0.874), similarly in patients refractory to PI + IMIDs (11.5 months vs. 9.2 months; p = 0.376). In RWE conditions, the median PFS in RRMM patients treated with Dara-Rd is shorter when compared to clinical trials. In heavily pretreated RRMM patients, efficacy of Dara-Rd treatment is limited; best possible outcomes of Dara-Rd are achieved in minimally pretreated patients.

Návaznosti

LX22NPO5102, projekt VaV

Název: Národní ústav pro výzkum rakoviny (Akronym: NÚVR)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro výzkum rakoviny, 5.1 EXCELES

NU21-03-00076, projekt VaV

Název: Využití MALDI-TOF hmotnostní spektrometrie pro identifikaci molekulárních vzorců u relabovaných pacientů s mnohočetným myelomem

Investor: Ministerstvo zdravotnictví ČR, Využití MALDI-TOF hmotnostní spektrometrie pro identifikaci molekulárních vzorců u relabovaných pacientů s mnohočetným myelomem, Podprogram 1 - standardní

Přiložené soubory

Daratumumab_with_lenalidomide_and_dexamethasone_in_relapsed_or_refractory_multiple_myeloma_patients_-_real_world_evidence_analysis.pdf

Citovat

ŠTORK, Martin; Ivan SPICKA; Jakub RADOCHA; Jiri MINARIK; Tomas JELINEK; Alexandra JUNGOVA; Petr PAVLICEK; Lenka POSPISILOVA; Frantisek SEDLAK; Jan STRAUB; Tomas PIKA; Zdeňka KNECHTOVÁ; Anna FIDRICHOVA; Ivanna BOICHUK; Sabina ŠEVČÍKOVÁ; Vladimir MAISNAR; Roman HAJEK a Luděk POUR. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. NEW YORK: SPRINGER, 2023, roč. 102, č. 6, s. 1501-1511. ISSN 0939-5555. Dostupné z: https://doi.org/10.1007/s00277-023-05188-4.

@article{2278163,
   author = {Štork, Martin and Spicka, Ivan and Radocha, Jakub and Minarik, Jiri and Jelinek, Tomas and Jungova, Alexandra and Pavlicek, Petr and Pospisilova, Lenka and Sedlak, Frantisek and Straub, Jan and Pika, Tomas and Knechtová, Zdeňka and Fidrichova, Anna and Boichuk, Ivanna and Ševčíková, Sabina and Maisnar, Vladimir and Hajek, Roman and Pour, Luděk},
   article_location = {NEW YORK},
   article_number = {6},
   doi = {https://doi.org/10.1007/s00277-023-05188-4},
   keywords = {Multiple myeloma; Treatment; Response rate; Relapse},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of Hematology},
   title = {Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis},
   url = {https://link.springer.com/article/10.1007/s00277-023-05188-4},
   volume = {102},
   year = {2023}
}

TY  - JOUR
ID  - 2278163
AU  - Štork, Martin - Spicka, Ivan - Radocha, Jakub - Minarik, Jiri - Jelinek, Tomas - Jungova, Alexandra - Pavlicek, Petr - Pospisilova, Lenka - Sedlak, Frantisek - Straub, Jan - Pika, Tomas - Knechtová, Zdeňka - Fidrichova, Anna - Boichuk, Ivanna - Ševčíková, Sabina - Maisnar, Vladimir - Hajek, Roman - Pour, Luděk
PY  - 2023
TI  - Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
JF  - Annals of Hematology
VL  - 102
IS  - 6
SP  - 1501-1511
EP  - 1501-1511
PB  - SPRINGER
SN  - 09395555
KW  - Multiple myeloma
KW  - Treatment
KW  - Response rate
KW  - Relapse
UR  - https://link.springer.com/article/10.1007/s00277-023-05188-4
N2  - We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of clinical trials in all major Czech hematology centers. As a reference, 531 RRMM patients treated with Rd were evaluated. Patients’ data were recorded in the Czech Registry of Monoclonal Gammopathies (RMG). Partial response (PR) or better response (ORR) was achieved in significantly more patients in Dara-Rd than in Rd group (91.2% vs. 69.9%; p < 0.001). The median progression free survival (PFS) was 26.9 months in the Dara-Rd and 12.8 months in the Rd group (p < 0.001). Median overall survival (OS) was not reached in the Dara-Rd compared to 27.2 months in the Rd group (p = 0.023). In patients with 1–3 previous treatment lines, there was significant PFS benefit of Dara-Rd compared to Rd (median PFS not reached vs. 13.2 months; p < 0.001). In patients with > 3 previous treatment lines, there was no significant PFS benefit of Dara-Rd treatment (7.8 months vs. 9.9 months; p = 0.874), similarly in patients refractory to PI + IMIDs (11.5 months vs. 9.2 months; p = 0.376). In RWE conditions, the median PFS in RRMM patients treated with Dara-Rd is shorter when compared to clinical trials. In heavily pretreated RRMM patients, efficacy of Dara-Rd treatment is limited; best possible outcomes of Dara-Rd are achieved in minimally pretreated patients.
ER  -

ŠTORK, Martin; Ivan SPICKA; Jakub RADOCHA; Jiri MINARIK; Tomas JELINEK; Alexandra JUNGOVA; Petr PAVLICEK; Lenka POSPISILOVA; Frantisek SEDLAK; Jan STRAUB; Tomas PIKA; Zdeňka KNECHTOVÁ; Anna FIDRICHOVA; Ivanna BOICHUK; Sabina ŠEVČÍKOVÁ; Vladimir MAISNAR; Roman HAJEK a Luděk POUR. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. \textit{Annals of Hematology}. NEW YORK: SPRINGER, 2023, roč.~102, č.~6, s.~1501-1511. ISSN~0939-5555. Dostupné z: https://doi.org/10.1007/s00277-023-05188-4.

Přehled o publikaci